Cantheon Capital is passionate about the pharmaceutical development of cannabinoids and psychedelic drugs.

We support early and mid-stage companies looking to make advances through clinical trials with a view to create novel FDA registered pharmaceuticals.

Our expertise is in understanding which Bio Pharma companies are likely to achieve success through a combination of

  • Great


  • Great


  • Great


  • Great


“Without knowledge action is useless and knowledge without action is futile.”

About Us

Cantheon Capital supports cannabinoid and psychedelic biotechs with corporate advisory, capital funding and detailed scientific advice.

We deploy capital to assist biotechs to achieve their drug development goals. Very simple.

“To acquire knowledge, one must study; but to acquire wisdom, one must observe”


We invest in listed biotech stocks with near term (<6 months) catalysts:

Listed biotechs only (NASDAQ, NYSE, TSX, CSE, LSE, ASX)

Near term catalysts

Cannabinoid or psychedelic assets only

Experienced research team

Cheque size = $500,000 to $10m

Must use approved CRO for trials

Must commence next clinical trial within 6 months

Funds payable on drawdown for step-wise research activity

Convertible loan, straight equity or straight debt options available

Corporate advisory recommended

Preclinical studies (Toxicology and CMC) complete and IND open (preferably)


Upcoming phase 1,2 and
3 clinical trials

Dossier Submissions

Upcoming dossier submissions
for Marketing Authorisation

BA/BE bridge

BA/BE bridge studies for 505j
and 505(b)2 studies


Aaron Ray

General Partner

Aaron serves as General Partner for Cantheon Capital with over 20 years’ experience in private equity & venture capital, business development, leadership development, consulting, and investing.

Extensive experience in corporate growth, strategy, and operational matters. Prior to his role as General Partner at Cantheon Capital, Aaron was the Managing Partner for Global Life Sciences Executive Search Firm, Proclinical Executive and Co-founder, CEO & Chairman of STM Canna. He also served as an Operating Partner with Transition Capital Partners and Greenway Capital Markets

With a strong understanding of clinical research business development and alternative assets, Aaron leads the investment decision team made up of strategic advisors from a variety of backgrounds including medical, scientific, capital markets and corporate development. Aaron received a Bachelor of Science from Oklahoma State University and his MBA from Texas Christion University.

Dr . Sud Agarwal

Dr . Sud Agarwal

Medical Advisor

MB ChB (UK), BSc (Hons), FANZCA (Australia)

Specialist Anesthesiologist
Experienced physician researcher
ASX/ NASDAQ Company Director
Global Cannabinoid Expert

Rob Jenny

Darryl Davies

Industry Advisor

BSc (Hons), DipMgmt

Company director for ASX and NZX companies dedicated to cannabinoid drug development
Director of a further 14 private companies in the cannabis sector.
Deep global connections in the cannabinoid and psychedelic industries.
Extensive sales, regulatory and award-winning physician education experience.

William Cronin

William Cronin

Investment Advisor


20+ years of experience in finance and capital markets at renowned global firms
Medical technology industry holding COO, CEO, and board positions
Deputy Chairman with Dignitana AB, (NASDAQ), Chairman of the Board of C3 Device Partners.

Rob Jenny

Dr. Rob Jenny

Scientific Advisor

BA, BSC(Hons), PhD (Monash University), GDBA, GradCert Commercialising Research

Experienced Researcher
Commercialization Specialist
ASX Company Director
Pharma Manufacturing


  • Dallas Office Address
    4925 Greenville Avenue,
    Dallas, Texas 75206

  • Singapore Office Address
    160 Robinson Road #14-04
    Singapore 068914

  • London Office Address
    Canada Square, Canary Wharf, London,
    Greater London E14 5AA

© 2022 Cantheon Capital. All Rights Reserved. Privacy Policy Terms of Use

Cantheon Capital